Previous 10 | Next 10 |
2024-04-06 08:38:09 ET More on Johnson & Johnson Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare ...
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approved CA...
2024-03-19 11:47:20 ET More on Legend Biotech Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) Johnson & Johnson wins FDA AdCom backing for Carvykti label expansion Legend Biotech FY 2023 Earnings Preview Read the full artic...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report . The inaugural report provides an overview of Legend Biotech’s ESG program and reporting in alignment with the ...
2024-03-16 07:58:13 ET More on Bristol-Myers, 2seventy bio, etc. Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conf...
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARTITUDE-4 study Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the U.S. Food and Drug Administration (FD...
2024-03-15 13:25:53 ET More on J&J, Legend Biotech, etc. Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare Conference (Transcript) Johnson & Johnson (JNJ) Leerink P...
2024-03-15 06:15:42 ET Summary Legend Biotech's share price is little changed despite concerns raised by the FDA in AdCom briefing documents. The increased rate of early deaths in the CARTITUDE-4 trial could reduce the use of Carvykti in later lines of multiple myeloma. Carved...
2024-03-13 09:23:45 ET More on Bristol-Myers, Johnson & Johnson, etc. Johnson & Johnson (JNJ) Leerink Partners Global Biopharma Conference (Transcript) Bristol-Myers Squibb: Finally Trending Up Bristol-Myers Squibb: Turnaround Expected J&J submits...
2024-03-13 08:29:15 ET Read the full article on Seeking Alpha For further details see: KB Financial, BeiGene, Legend Biotech among premarket gainers' pack
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...
VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, s...
2024-06-17 07:00:07 ET Asthika Goonewardene from Truist Financial issued a price target of $88.00 for LEGN on 2024-06-17 06:19:00. The adjusted price target was set to $88.00. At the time of the announcement, LEGN was trading at $42.45. The overall price target consensus...